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Abstract
Background: Health related quality of life (HRQOL) is patient-reported, and an important treatment outcome
for patients undergoing renal replacement therapy. Whether HRQOL in dialysis can affect mortality or graft
survival after renal transplantation (RTX) is not determined. The aims of the present study were to investigate
whether pretransplant HRQOL is associated with post-RTX patient survival or graft function, and to assess
whether improvement in HRQOL from dialysis to RTX is associated with patient survival.
Methods: In a longitudinal prospective study, HRQOL was measured in 142 prevalent dialysis patients
(67 % males, mean age 51 ± 15.5 years) who subsequent underwent renal transplantation. HRQOL could
be repeated in 110 transplant patients 41 (IQR 34–51) months after RTX using the self-administered Kidney
Disease and Quality of Life Short Form (KDQOL-SF) measure. Kaplan-Meier plots were utilized for survival
analyses, and linear regression models were used to address HRQOL and effect on graft function.
Results: Follow-up time was 102 (IQR 97–108) months after RTX. Survival after RTX was higher in patients
who perceived good physical function (PF) in dialysis compared to patients with poorer PF (p = 0.019). Low
scores in the domain mental health measured in dialysis was associated with accelerated decline in graft
function (p = 0.048). Improvements in the kidney-specific domains “symptoms” and “effect of kidney disease”
in the trajectory from dialysis to RTX were associated with a survival benefit (p = 0.007 and p = 0.02,
respectively).
Conclusion: HRQOL measured in dialysis patients was associated with survival and graft function after RTX.
These findings may be useful in clinical pretransplant evaluations. Improvements in some of the kidney-specific
HRQOL domains from dialysis to RTX were associated with lower mortality. Prospective and interventional
studies are warranted.
Background
Patients with end stage renal disease (ESRD) may be
treated with dialysis or renal transplantation (RTX). RTX
is considered superior to chronic dialysis, as it prolongs
survival and alleviates uremic symptoms [1, 2]. It is also
considered more cost-effective based on quality adjusted
life years [3]. Dialysis patients in Norway are considered
with regard to eligibility for RTX, independent of chrono-
logical age. During the last decades, short-term graft and
patient survival have improved due to upgraded surgical
procedures, more efficient immunosuppressive regimens
and improved care for complications and comorbidities.
However, long-term term attrition rates for renal grafts
have only shown small improvements, and survival in
RTX patients is reduced compared to the general popula-
tion [4–6].
Patient-related outcome measures (PROMs) have be-
come important as they may capture the impact of disease
perceived by the patients themselves. PROMs in a clinical
setting are important for both the patient and the health
provider as they may lead to more adequate intervention
and treatment. The concept health-related quality of life
(HRQOL) is an example of a PROM, and includes the
subjective perception of e.g. physical function, mental
well-being and social aspects.
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Although aspects of HRQOL may improve after RTX
compared with dialysis [7, 8], generic HRQOL is reported
inferior by transplanted patients compared to that of the
general population [1, 9]. Disease-specific HRQOL instru-
ments may reveal other aspects of clinical importance
than the generic tools, and unmask more subtle changes.
Our group has recently reported that kidney-specific
domains closely related to daily life complaints and nui-
sances improved the most after RTX [9].
HRQOL has been shown to be a predictor of morbidity
and mortality in dialysis patients, also after multiple
adjustments [10–12]. In a large, prospective study by Mol-
nar Varga et al. [13], poor HRQOL measured after RTX
was associated with mortality and graft failure. These
observations support that PROMS are important in the
follow-up of RTX patients.
Whether self-perceived physical function reported
during dialysis may be associated with mortality after
renal transplantation has recently been addressed in two
trials [14, 15]. Both reported that pretransplant physical
function was associated to survival after RTX. Whether
other aspects of HRQOL measured in dialysis could
predict mortality after RTX has not been addressed.
Deteriorating renal graft function is associated with
immunologic and non-immunologic factors, including
reduced HRQOL measured after RTX [16–18]. Whether
poor HRQOL during the time of dialysis may be related
to graft function has not previously been addressed. Nor
do we know whether improvement in HRQOL in the
transition from dialysis to transplantation may be asso-
ciated with survival.
We hypothesized that poor HRQOL during dialysis
could be related to mortality and reduced graft function
after RTX, and that patients with improvement in HRQOL
from dialysis to transplantation had better survival com-
pared to patients without improvement. Thus, the aims of
our study were to explore whether generic or kidney-
specific HRQOL measured during chronic dialysis was
associated with mortality or graft function after successful
renal transplantation. Secondly, to assess whether im-
proved self-perceived HRQOL in the transition from dialy-
sis to transplantation could be related to patient survival.
Methods
Between August 2005 and February 2007, a total of 301
prevalent dialysis patients from 10 different hospitals in
Norway were included in a cross-sectional study address-
ing HRQOL issues. The study details have been described
previously, and are therefore only briefly presented here
[19]. All patients >18 years receiving either hemodialysis
(HD) or peritoneal dialysis (PD) for more than two
months were invited to participate. Patients came from
both rural and urban areas. Cognitive dysfunction, major
psychiatric disorder and inadequate Norwegian language
skills were exclusion criteria. Hospitalization during the
investigation period led to exclusion, but patients could be
enrolled four weeks or more after hospital discharge if
they were clinically stable. The questionnaires were
answered by the patients during a regular HD session or
during a scheduled visit for the PD patients.
In 2010–2011, a follow-up study was conducted,
where patients who had taken part in the first study
were invited to participate, whether they had undergone
renal transplantation or were still in dialysis. Inclusion
and exclusion criteria were unchanged from the previous
study, except for the dialysis criteria. Transplanted
patients completed the questionnaires during a regular
visit at the renal outpatient clinic [9]. The present study
provides results from transplanted patients only.
Clinical and demographical data were collected from
hospital charts and/or direct questioning of the patients.
Renal transplantation, graft function, patient survival, and
cause of death were reported by the Norwegian Renal
Registry [20]. Estimated glomerular filtration rate (eGFR)
was calculated on the basis of the simplified Modification
of Diet in Renal Disease prediction equation [21]. Graft
function was defined as eGFR. Comorbidity was mea-
sured using the modified Charlson comorbidity index
(CCI) [22, 23]. CCI has been validated for dialysis patients
[23] and kidney transplanted patients [24], and is a com-
posite score of age and 19 weighted comorbid conditions,
including coronary artery disease, congestive heart failure,
cerebrovascular disease, diabetes, malignancy and chronic
pulmonary disease. Diabetes as a comorbid condition
scored one point, and diabetes as cause of ESRD scored
two points. In the present study, CCI was also calculated
without including age in order to enable evaluation of age
as a separate variable in multivariate analysis.
HRQOL
The self-administered Kidney Disease and Quality of Life
Short Form measure version 1.3 (KDQOL-SF) [25] con-
sists of a kidney-specific and a generic part. The kidney-
specific part contains 43 kidney-specific items that are
summarized into 11 domains, i.e. symptoms, effect of
kidney disease, burden of kidney disease, cognitive func-
tion, quality of social interaction, sleep, sexual function,
social support, dialysis staff encouragement, patient satis-
faction with care and work status. The generic part of
KDQOL-SF comprises the Medical Outcome Study 36-
item Short Form Health Survey (SF-36) [26]. It consists of
36 items summarized into the eight conceptual domains
physical function, limitation due to physical problems,
bodily pain, general health, vitality, social function, limita-
tion due to emotional problems, and mental health. Scores
in KDQOL-SF were transformed into linear 0–100 point
scores, with higher scores indicating better quality of life.
KDQOL-SF has been validated for kidney transplanted
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patients and dialysis patients [27, 28]. In the present study,
the item concerning dialysis access was not included in
the KDQOL domain “symptoms”, as it is irrelevant for
transplanted patients.
Half a standard deviation (SD) of the baseline score in
each HRQOL domain was chosen as a measure of clinical
relevant change in HRQOL from dialysis to RTX [29].
This is equivalent to Cohen’s d effect size of = 0.50 [30].
According Cohen’s d, an effect size of 0.2–0.5 is regarded
a small effect, 0.5–0.8 a medium effect and 0.8 to infinity
a large effect.
Statistics
Clinical and demographic data were presented as mean
with SD if assumptions of normality were fulfilled, or as
median with interquartile range (IQR) if data were
skewed. Percentages were given for categorical variables.
Dependent on the distribution of the variables, Student’s t-
test or Mann–Whitney U test were used for comparison
between two groups. Chi-square test was used to compare
categorical variables. The observation period for the
survival analyses was defined as time from transplantation
until death or study end (May 2015).
Kaplan-Meier curves and log-rank statistics were ap-
plied to identify significant differences in survival. Death
(including death after return to dialysis) was defined as
end point. All the KDQOL-SF domains were investigated
regarding survival except “dialysis staff encouragement”
and “satisfaction with care”, as these domains were con-
sidered not relevant in transplanted patients. Based on
pretransplant HRQOL scores, patients were categorized
by tertile levels, and survival differences between the three
patient groups were assessed.
Survival was compared between patients with clinical
relevant improvement and patients with no clinical rele-
vant improvement in the transition from dialysis to trans-
plantation. The product term of age and HRQOL domains
was entered in Cox regression analyses to check for inter-
action regarding survival.
Multiple linear regression analyses were performed with
yearly eGFR decline as dependent variable. 1-year post-
transplant eGFR was used as the reference point for calcu-
lating yearly decline, as eGFR levels might fluctuate during
the first months after transplantation. For patients with
graft loss, eGFR was set as zero the year they returned to
dialysis. Patients who lost their graft or died within one
year after transplantation were excluded in the regression
analyses. Independent variables were age, gender, HRQOL
domains, and comorbidity (CCI score without including
age to avoid double adjustment for age). These variables
were chosen on a clinical basis. The assumptions of linea-
rity of continuous variables were checked and found to be
adequately met.
Missing values in the generic part of KDQOL-SF were
substituted with the patient’s mean score if less than half
of the items were missing. No substitution was done in
the kidney-specific part, if a question was left unanswered,
the total score was calculated as suggested by the RAND
group [25]. Missing data were treated by pairwise deletion
in the statistical analyses.
All data were analysed using SPSS for Windows version
22 (IBM SPSS Statistics, New York, USA). Level of signifi-
cance was set to p < 0.05.
Results
HRQOL measured in dialysis and survival
Of the 301 prevalent dialysis patients who had completed
the HRQOL questionnaires in 2005–2007, 142 were sub-
sequently transplanted (Fig. 1). Clinical and demographic
characteristics are given in Table 1. The immunosuppres-
sive regimen of cyclosporine/mycophenolate mofetil/
prednisolone was used in 43 %, while 39 % used a com-
bination of tacrolimus/mycophenolate mofetil/prednisol-
one. Median time from baseline to RTX was 11 (range
0–64) months, time from RTX to death or study end
was 7.4 (0.8–9.7) years.
Differences in all-cause mortality after RTX appeared
in the Kaplan-Meier survival plot between tertiles of
patients with different scores of “physical function” mea-
sured in dialysis (p = 0.063). The two upper tertiles (with
the best physical function) were combined as the curves
were close and different from the curve of those with
the worst perceived physical function (Fig. 2). Five years
after RTX, 88 % of patients with good physical function
(the upper two tertiles) were alive, and 83 % of patients
with poor physical function (the lower tertile). No inter-
action between age and physical function was found (p =
0.38). Patient characteristics in the groups of poor vs.
better physical function are given in Table 2. No other
pretransplant KDQOL-SF domains were associated to
survival after RTX.
HRQOL in dialysis and graft function
Within the first year post-RTX two patients died, one of
them experienced graft loss prior to death, and another
three patients lost their graft within one year. These
patients were not included in the regression analyses
regarding GFR decline.
Mean GFR one year post-RTX was 60 ± 21 ml/min/
1.732, with a mean yearly eGFR decline of 2.4 ± 5.4 ml/
min/1.732. After adjustment for age, gender and comor-
bidity in a multivariate linear regression model, lower
pretransplant score in the domain “mental health” was
associated with worsened graft function, i.e. a larger
yearly decline in eGFR (p = 0.048) (Table 3). None of the
other generic or kidney-specific HRQOL domains were
associated with graft function.
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Change in HRQOL from dialysis to transplantation and
survival
Of the 142 transplanted patients, 110 participated in the
follow-up study, providing data of change in HRQOL
scores from dialysis to RTX. Baseline KDQOL-SF scores
(in dialysis) of these patients and the proportion with
clinical relevant change from dialysis to RTX are given in
Table 4. Reasons for not taking part in the follow-up study
were exclusion due to mental deterioration or prolonged
hospitalization (n = 19), death before follow-up (n = 5),
returned to dialysis or still in dialysis at time of follow-up
(n = 5) and unwillingness (n = 3). The patients participa-
ting in the follow-up study did not differ in age, gender or
comorbidity from those who did not take part, and the
KDQOL-SF scores differed in two domains only, cognitive
function (85 ± 17 vs. 74 ± 20, p = 0.001) and sexual func-
tion (71 ± 31 vs. 54 ± 33 p = 0.03) respectively.
Kaplan-Meier curves revealed a survival advantage for
patients with clinical relevant improvement from dialysis
to transplantation in the HRQOL domains “symptoms” (p
= 0.007) and “effect of kidney disease” (p = 0.02) compared
to patients with no improvement or deterioration (Figs. 3
and 4). Five years after RTX, 96 % of the patients with
improvement in symptoms were alive and 85 % of the
patients with no improvement. For “effect of kidney
disease”, the proportion of patients alive after five years
was 94 % amongst those with improvement, and 84 % for
patients with no improvement. Patient characteristics of
the groups with and without clinical relevant improve-
ment in symptoms and effect of kidney disease are given
in Table 5. There was no statistical interaction between
age and “symptoms” (p = 0.15) or between age and “effect
of kidney disease” (p = 0.40) in the Cox regression survival
analyses. Changes in the generic HRQOL (SF-36) domains
from dialysis to transplantation did not predict survival
Discussion
This prospective study is the first to address whether pre-
transplant generic and kidney-specific HRQOL domains
measured in dialysis were associated with survival after
renal transplantation. That a single domain, i.e. physical
function, obtained during dialysis could serve as an indica-
tor of survival after renal transplantation, is an important
finding with possible clinical implications for the pretrans-
plant evaluation.
Both kidney-specific and generic HRQOL domains have
been found to be independent predictors of survival in
dialysis patients, even after multiple adjustments, with
physical function as the most powerful predictor [10, 12].
Physical aspects of HRQOL measured after transplantation
Fig. 1 Flowchart of enrolment
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are also independently associated to survival [13, 17]. Only
two studies have previously addressed whether HRQOL
measured during dialysis could affect survival after trans-
plantation [14, 31]. Kutner et al. [14] reported that poor
pretransplant physical function affected the combined
endpoint hospitalization and death six years after trans-
plantation. As the number of deaths was very low, only
five, the endpoint seemed driven mainly by hospitalization.
That death rate was much lower than what has been
reported in other transplantation registries [32–34]. The
inclusion criteria in that study may have favoured younger
and possibly healthier patients with short time in dialysis
before RTX. Furthermore, contrasting the present study,
71 % of the patients had been treated with peritoneal
dialysis suggesting a certain selection of patients.
During the preparation of the present manuscript, a
large retrospective registry study from the US was
published, including 10875 patients subsequently trans-
planted [31]. Only the SF-36 domain “physical function”
was investigated with regard to survival, and the authors
concluded that poor functional status predicted 3-year
mortality after transplantation. This is in accordance
with our results from a much smaller cohort. In our
prospective study, several other domains of generic and
kidney-specific HRQOL were assessed with regard to
survival. Thus, albeit small, the present study added new
information, suggesting that the only KDQOL-SF do-
main measured in dialysis that was associated to survival
after RTX, was the physical function. The large US regis-
try study [15] corroborated our findings that the effect
of physical function on survival was not affected by age,
as no interaction was found. Johansen et al. [35] suggested
that frailty in dialysis patients could be assessed using
self-reported physical function (SF-36) rather than cum-
bersome objective testing. Frailty is a multidimensional
Table 1 Demographic and clinical characteristics of patients in
dialysis (n = 142) who were subsequently renal transplanted.






Age 46.9 ± 14.5 63.6 ± 10.9 < 0.001
Gender, male % 63.5 78.8 0.10
Time of follow up, months 106 (101–111) 76 (64–85) < 0.001
Dialysis vintage, months ǂ 7 (4–15) 9 (3–23) 0.32
Peritoneal dialysis, % 23 15 0.31
Waitlisted for RTX, % 68 60 0.40
Living donor, % 29 17 0.17
Hypertension, % 89 85 0.58
Cardiovascular disease, % 11 31 0.005
Charlson comorbidity index 4 (2–6) 6 (5–7) 0.001
Diabetes, % 23 15 0.32
Body mass index, kg/m2 25.4 ± 4.4 25.7 ± 4.2 0.52
Systolic blood pressure, mmHg 140 ± 20 148 ± 18 0.02
Diastolic blood pressure, mmHg 81 ± 12 76 ± 10 0.05
Haemoglobin, g/dL 12.3 ± 1.5 12.1 ± 1.4 0.30
Albumin, mmol/L 39 (38–42) 41 (37–43) 0.53
Cause of end stage renal disease, %
-Diabetic nephropathy 15 0 0.02
-Nephrosclerosis 14 32 0.02
-Glomerulonephritis 33 21 0.52
-Inherited cystic kidney disease 10 18 0.28
-Other 27 29 0.82
Fig. 2 Kaplan-Meier plots showing survival of renal transplant patients with better vs. poorer scores in “physical function” obtained during dialysis
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construct describing vulnerability to various stressors
[36]. The classic diagnostic criteria of frailty imbed both
self-reported physical impairment and objective testing of
muscle weakness. Frailty has been associated with disabi-
lity, morbidity and mortality in older persons [36, 37].
Numerous dialysis patients suffer from severe neuropathy,
myopathy and muscle weakness due to the kidney disease
and possibly the dialysis treatment, explaining the high
prevalence of frailty also in younger patients [38]. Comor-
bidity also contributes to frailty, and we observed that
patients with better self-reported physical function had
less comorbidity in the present study. That frailty observed
in patients while in dialysis may affect mortality even after
they have undergone renal transplantation, needs to be
confirmed in larger, prospective studies.
If a single domain in KDQOL-SF, physical function,
measured in dialysis may predict survival after RTX, this
could be of clinical importance as it might serve to iden-
tify patients at increased risk after RTX. Furthermore, it
may remind clinicians that physical activity in dialysis
patients should be recommended as suggested in the
Kidney Disease Outcomes Quality Initiative guidelines
[39]. Self-reported physical activity has been shown to be
associated with mortality and HRQOL both in dialysis
patients and RTX patients [40, 41], but causality is not
established and larger interventional studies are awaited.
Yet another exciting and novel finding in the present
study was that the domain mental health measured in
dialysis was associated with graft function after RTX, even
after multiple adjustments. Actually, in the regression
model, poor mental health in dialysis was the only variable
that predicted an accelerated loss of graft function. That
pretransplant scores in mental health predicted decline in
graft function has not previously been addressed. How-
ever, mental health as well as the mental composite score
measured several years after transplantation has been
shown to predict graft loss [13]. That effect on graft loss
could not be confirmed in a later study of transplanted
patients [17].
We have previously shown that there is surprisingly
small changes in mental health from dialysis to transplan-
tation [9]. Poor mental health is closely related to depres-
sive symptoms [42, 43], which may increase the risk of
non-adherence of immunosuppressive medication after
transplantation [44]. Non-adherence in transplanted
patients can be substantial [45], and enlarges the risk of
graft failure [46]. Other factors contributing to accelerated
graft decline in patients with poor mental health are likely
Table 2 Characteristics of patients (n = 142) with different






Agea 56 ± 14 50 ± 16 0.03
Female,% 34 32 0.64
Comorbidityb 5 (4–7) 4 (3–6) 0.02
Time in dialysisa 2.3 (1.5–3.5) 1.7 (1.1–2.5) 0.01
Albuminc 39.2 ± 4.4 39.6 ± 4.3 0.82
Living donor,% 17 32 0.06
Data presented as mean ± standard deviation or median with interquartile
range as appropriate
aAt time of renal transplantation, in years; bCharlson Comorbidity Index in
dialysis; cIn dialysis, mmol/l
Table 3 Linear regression model showing associations of yearly
decline in graft function in kidney transplanted patients (n = 137)
Yearly GFRa decline, ml/min/1.73 m2
B p
Mental healthb, +10 points - 0.5 0.048
Agec,+10 years - 0.3 0.29
Gender, female 0,3 0.47
Comorbidityd, +1 point 0.4 0.32
aGlomerular filtration rate. Higher values of yearly decline indicate more rapid
loss of graft function from reference value one year after transplantation.
bMental health measured in dialysis. cAge at time of transplantation. dCharlson
comorbidity index without adding points for age
Table 4 KDQOL-SF scores in dialysis and after transplantation
(n = 110) and the proportion of patients with clinical relevant











69 ± 18 84 ± 16, 71
Burden of kidney
disease
39 ± 26 73 ± 27 71
Symptoms 74 ± 16 82 ± 15 51
Work status 21 ± 35 45 ± 42 44
Sleep 61 ± 21 69 ± 20 35
Sexual function 71 ± 31 85 ± 20 25
Cognitive function 85 ± 17 88 ± 14 18
Social support 78 ± 28 83 ± 27 35
Quality of social
interaction
82 ± 18 80 ± 18 23
Physical function 68 ± 24 74 ± 28 31
Role physical 36 ± 41 54 ± 44 44
General health 47 ± 22 59 ± 26 50
Vitality 46 ± 22 55 ± 24 48
Bodily pain 66 ± 27 73 ± 28 38
Social functioning 70 ± 29 81 ± 26 34
Mental health 77 ± 18 78 ± 19 26
Role emotional 65 ± 41 71 ± 42 27
aImprovement in score from dialysis to transplantation > 0.5 SD of the score
in dialysis
bScores previously presented as spider diagrams [9]
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numerous, including somatic, psychological, social and
socioeconomic dimensions. Possible clinical implications
of this finding should be closer follow-up of patients with
low scores in mental health in dialysis.
We observed that patients with perceived clinical relevant
improvement in the kidney specific domain “symptoms”
and “effect of kidney disease” had a survival advantage
compared to those without improvement. Comorbidity
might have been a contributing factor. The domain “effect
of kidney disease” encompasses questions about restrictions
in everyday life due to the kidney disease. Improvement
could reflect the perception of returning to “a normal life”
after transplantation.
Strengths and limitations
The prospective design, the representative cohort inclu-
ding a third of the prevalent dialysis population at the
time of investigation, and that none of the patients was
lost to follow-up, were important strengths of the study.
The quality of the data was good, with less than 1.5 %
Fig. 3 Kaplan-Meier plots showing survival of renal transplant patients with improvement vs. no improvement in “symptoms” from dialysis
to transplantation
Fig. 4 Kaplan-Meier plots showing survival of renal transplant patients with improvement vs. no improvement in “effect of kidney disease” from
dialysis to transplantation
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missing values in SF-36. Data on renal function and
mortality were complete. The acceptance criteria for renal
transplantation were based on national consensus. All
transplantations in Norway were performed in one national
center.
A limitation of the study was the size of the cohort and
the number of events. Due to the inclusion criteria, only
clinically stable patients without prolonged hospitalization
during the inclusion period, severe cognitive dysfunction,
psychiatric illness or drug abuse were included. This may
have led to selection bias towards healthier patients. As
the majority of patients were Caucasians, the applicability
to other populations may be limited. The transplantation
rate in Norway is high, the time in dialysis is short, and
the dialysis population in Norway may therefore differ
from other dialysis populations with less access to renal
transplantation [20]. Causality cannot be determined, as
the study design is observational. The likelihood of type 1
errors increases when multiple comparisons are per-
formed without statistical adjustments. This study is
observational and with a limited sample size, hence no
corrections were performed to avoid omitting of impor-
tant clinical findings. Thus, the findings should be inter-
preted with caution.
Conclusion
Poor physical function measured during dialysis was
associated with increased mortality up to seven years after
transplantation. This finding might have clinical implica-
tions. HRQOL measured in dialysis is a simple and time
effective tool that could easily be included as a supplement
to the pretransplant evaluation and particularly in recom-
mendations with regard to physical function. Of clinical
interest is also the finding that poor mental health in
dialysis patients was associated to accelerated decline in
graft function after RTX. Patients who perceive poor
mental health in dialysis may need closer follow-up in the
time after transplantation. Whether interventions to im-
prove physical function and mental health in dialysis could
affect survival even after transplantation needs to be
confirmed in larger studies.
Improvement in HRQOL in the transition from dialysis
to transplantation seemed to indicate improved survival.
This new finding needs to be addressed in future studies.
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